Precision Medicine in Oncology® Articles

Optimizing HER2-Targeted Therapy
Sara Hurvitz, MD, and Sunil Verma, MD, share their expert insight on the latest groundbreaking developments in HER2-positive breast cancer.
Managing Cardiac AEs in HER2-Positive Breast Cancer
Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.
Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer
Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.
Dual Targeting Advances in HER2+/HR+ Breast Cancer
The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.
Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs
Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.
Blood Test May Predict Palbociclib Response Earlier in Breast Cancer
A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance). 
European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer
European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.
Gastrointestinal Cancers Entering Age of Precision Medicine
Aiwu Ruth He, MD, PhD, discusses the future of precision medicine in gastrointestinal cancers.
Expert Highlights Evolving Options in HER2+ Breast Cancer
Tiffany A. Traina, MD, discusses her experiences with using neratinib and pertuzumab, and shares her excitement on the direction in which the HER2-positive breast cancer field is moving.
Network Enlists Practicing Oncologists to Develop Plans
Physicians are carefully evaluating potential partnership and referral deals to ensure that whatever they do is perceived as aligned with delivering better, more efficient care.
Publication Bottom Border
Border Publication